日韩A∨无码成人精品国产,激情A片久久久久久久,无码天堂va亚洲va在线va免费无码又爽又刺激高潮虎虎视频,伊人无码精品久久一区二区,婷婷激情五月一区二区三区播放中美女 赤裸 一区二区三区,精品亚洲成A人片在线观看少妇,亚洲欧美综合国产不卡,国产精品亚洲а∨天堂免

PhD

Dr. Biao Zheng graduated from the medical department of the Medical College of Zhejiang University with a bachelor's degree in clinical medicine. He received his MS and PhD in Immunology from Fudan University School of Medicine and King's College, University of London, respectively. Dr.  Zheng has taught at the University of Maryland School of Medicine and Duke University Medical Center. Subsequently, he served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng has published a number of papers in the world top journals such as Nature and Science.

Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. In 2015, he joined Johnson & Johnson as global vice president in Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific. Before joining BRL Medicine Inc., he joined IASO Biotherapeutics as the chief scientific officer 2020.

Dr. Zheng has more than 30 years of experience in the pharmaceutical industry, especially in the field of immunotherapy (macromolecular antibody, cell therapy, etc.). He has deep insights and experience in drug development, international medical environment, market access and commercialization.

PhD , Professor at East China Normal University

Dr. Li is a pioneer in the field of innovative genome editing tool development and CRISPR-based gene therapy. He has published more than 100 research articles in high impact journals, including Nature Biotechnology, Nature Genetics and Nature Cell Biology, and developed several novel editing tools, such as hyCBE and A&C-BEmax.

PhD , Post-Doctoral Harvard University, Researcher of East China Normal University

Researcher Yuxuan Wu has published more than 10 relevant research papers in recent years in several journals including internationally renowned academic journals Nature Medicine, Cell Stem Cell, Cell Research, Nature Genetics and Nature Biotechnology. A number of works have been widely recognized and highly evaluated by domestic and international peers, majoring in combining gene editing technology (CRISPR) with hematopoietic stem cell transplantation for the treatment of thalassemia and other blood disorders. He was selected as a "Zijiang Outstanding Young Scholar" of East China Normal University in 2018.

PhD , Professor of East China Normal University

Prof. Bing Du is mainly engaged in regulation of tumor immune microenvironment and cancer immune therapy. In recent years, he has published more than 40 SCI papers in the high impact journals such as Science Advances, Cancer Research, Cancer Immunology Research, Cellular & Molecular Immunology and Mucosal Immunology. Meanwhile, he has been authorized more than 10 national invention patents in the past few years.

PhD

Chris?Wang?graduated from Anhui Medical University in 1999, majoring in clinical medicine. He received his master's and doctor's degrees in oncology pharmacology from Wannan Medical College and Shanghai Institute of Pharmaceutical Industry. Chris Wang has 18 years of working experience in hospitals and pharmaceutical companies. He has held clinical development, medical affairs and pre-clinical research positions in Sanofi, Novartis, Junshi, JW, Genor, etc. Led/participated in clinical research and development work in solid tumors, hematologic malignancies, autoimmune diseases, neurological disease and rare diseases, etc. Participated in the formulation and interpretation of CDE guidelines for CGT industries several times, and gained extensive experience in early phase and pivotal studies in CGT, biological products, antitumor vaccines. Prior to joining BRL Medicine Inc., Chris Wang served as senior director and project lead of clinical development at JW Therapeutics.

PhD , AssociateProfessor

Jiqin Zhang is focused on the research of gene editing and tumor immune cell therapy. In recent years, he has published?more than 20 SCI papers?in international journals such as Nature,?Nature Communications, Cell Research, Molecular Cancer?and Hypertension. As a leader, he has taken charge of?two projects of National Natural Science Foundation of China?and one project of Shanghai Natural Science?Foundation.?He also participated in several?national and provincial scientific research projects. He has developed an international first non-viral?genome specific targeted CAR T cell technology, established the Quikin CART^? platform?with BRL proprietary intellectual property, providing new strategies to break through the limitations of current CAR T cell therapy.

PhD

During his graduate studies, Dr. Binghe Tan focused on the role and mechanism of G protein-coupled receptors and their signaling in the regulation of tumor immunity, exploring the regulation of G protein-coupled receptor-mediated immune cell function and revealing the important roles?and mechanisms?of macrophages, T cells and other immune cells in the tumor microenvironment. In addition, he has been working on immunotherapy based on the regulation of tumor immune microenvironment. His postdoctoral work focuses on the genericization and functional enhancement of chimeric antigen receptor T cells (CAR-T) using gene editing technology, as well as the development and optimization of engineered T cell preparation processes, with the aim of achieving safety, efficacy and stability goals of universal CART (UCART) in clinical translational applications. He has been published as first author and co-author in Cancer Research, Journal of Immunology, Journal of Biological Chemistry, Science China Life Sciences, Cellular & Molecular Immunology, etc. He has applied for one international invention patent and four Chinese invention patents, one of which has been transferred. He presided over one National Natural Science Foundation of China (NSFC) youth project and participated in several NSFC surface projects as a key technicaldirector.

MBA of Wuhan University

CPM^? International Certified Property Manager, Certified Instructor of Leadership and Human Resource ManagementNan Xu has worked in human resource management in Dowell Group, Shimao Group, China Resources Group and China Vanke. She has served as HR administrative director of commercial section, assistant HR director of the group, head of HR administration of regional companies, and senior manager of performance management of the group. Has nearly twenty years of experience in organizational development, corporate culture and talent management. Served as a volunteer for the Dima Charity Foundation during the novel coronavirus outbreak, coordinating the procurement of overseas medical supplies. Now she is responsible for the management of human resources, administration and public affairs of the company.

Ph.D. in Immunology, Post-Doctoral, East China Normal University

Dr. Na Zhang has long been engaged in the field of cancer immune therapy, especially in cell therapy.

She has developed innovative solid tumor CAR T cell products（Prostate Cancer, Gastric Cancer & Ovarian Cancer et.al.）.

She has hosted National Natural Science Foundation of China & Postdoctoral Foundation, and published several SCI papers in well-known international journals.

Meanwhile, she has been authorized more than 10 national invention patents.

Anling?Huang?graduated from East China Normal University with a Master's degree in Biochemistry and Molecular Biology. She won the nomination award of top 30 cutting-edge women in China's intellectual property circle in 2021 and published 3 papers in International Academic Journals. Anling is responsible for company's Intellectual Property & Marketing?affairs, and has led the company to obtain honorary titles such as "Shanghai patent pilot enterprise" and "intellectual property management system certification certificate".